

# Expression of Syk and MAP4 proteins in ovarian cancer

Siwei Zhang<sup>1</sup>, Suha Deen<sup>2</sup>, Sarah J Storr<sup>1</sup>, Anqi Yao<sup>1</sup>, Stewart G Martin<sup>1,3</sup>

1 Academic Clinical Oncology, Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, UK.


2 Department of Pathology, Queen's Medical Centre, Nottingham University Hospital, Nottingham, NG7 2UH, UK

3 Corresponding author: Academic Clinical Oncology, Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, UK

Telephone: +44(0)115 823 1846

Email: [stewart.martin@nottingham.ac.uk](mailto:stewart.martin@nottingham.ac.uk).

## Supplements



**Fig. S1 The specificity of anti-Syk and anti-MAP4 antibody.** Syk and MAP4 expression across the panel of ovarian cancer cell lines were detected by Western blotting analysis. Primary antibodies were diluted in 1:1000 dilution. A single band corresponding to the molecular mass of the intended target was observed in the Western blotting studies which indicated the specificity of both anti-MAP4 (BETHYL LABORATORIES, UK) and anti-Syk (Thermo Fisher SCIENTIFIC, UK) antibody. Figures present the representative blots of 2 independent experiments with lysates from cells with different passage numbers. Open arrows indicate  $\beta$ -actin (42 kDa) which was used as the loading control. Black arrows indicate Syk (72 kDa) and MAP4 (210 kDa), respectively. Lane M: Protein marker, Lane 1: A2780, Lane 2: A2780-cis, Lane 3: SKOV3, Lane 4: PEO1, and Lane 5: PEO4.

**Table S1 The association between protein expression and tumour stage**

Variable	Syk-c			Syk-n			MAP4		
	Low	High	P-value	Low	High	P-value	Low	High	P-value
<b>Stage</b>									
<b>Tumour confined to ovaries (stage 1)</b>	36(8.3%)	123 (28.3%)	<b>0.002</b>	50 (11.5%)	109 (25.1%)	<b>0.041</b>	75 (17.2%)	89 (20.5%)	<b>0.000087</b>
<b>Tumour spread out of ovaries (stage 2, 3 and 4)</b>	31 (7.1%)	244 (56.2%)		62 (14.3%)	213 (49.1%)		74 (17.0%)	197 (45.3%)	
<b>Stage</b>									
<b>Without distant metastasis (stage 1,2 and 3)</b>	62 (14.3%)	341 (78.6%)	0.912	104 (24.0%)	299 (68.9%)	1.000	139 (32.0%)	265 (60.9%)	0.808
<b>Distant metastasis occurred (stage 4)</b>	5 (1.2%)	26 (6.0%)		8 (1.8%)	23 (5.3%)		10 (2.3%)	21 (4.8%)	

Significant *P* values are indicated by bold font.

**Table S2 P values from the log-rank test of overall survival in different subgroups**

Variables	P value		
	MAP4	Cytoplasmic Syk	Nuclear Syk
<b>Histological subtypes</b>			
High grade serous carcinoma	0.699	0.581	0.506
Mucinous carcinoma	0.791	0.026	0.115
Endometrioid carcinoma	0.110	0.188	0.006
Clear-cell carcinoma	0.988	0.822	0.453
Low grade serous carcinoma	0.212	0.549	0.196
<b>Stage</b>			
Stage 1 (confined tumour) (n=152)	0.679	0.002	<b>0.001</b>
Stage 2, 3 & 4 (tumour spread) (n=269)	0.404	0.688	0.224
<b>Stage</b>			
Stage 1, 2 & 3 (without distant metastasis) (n=390)	0.104	0.568	0.107
Stage 4 (with distant metastasis) (n=31)	0.061	0.402	0.509
<b>Sensitivity to platinum-based chemotherapy</b>			
Sensitive (n=195)	0.885	0.486	0.464
Resistant (n=40)	0.996	0.016	<b>0.001</b>
<b>Residual disease</b>			
No residual tumour (n=232)	0.867	0.054	<b>0.001</b>
residual tumour (n=147)	0.540	0.349	0.571

Significant P values are indicated by bold font.

**Table S3 P values from the log-rank test of overall survival related to combinational protein expression.**

	Syk-c (P=0.494)	Syk-n (P=0.113)	MAP4 (P=0.064)	CXCL4 (P=0.031)	CXCR3 (P=0.182)
Calpastatin (P=0.010)	0.174	0.178	0.024	0.225	0.188
Calpain-1 (P=0.153)	0.273	0.292	0.283	0.309	0.445
Calpain-2 (P=0.026)	0.087	0.056	0.037	0.285	0.152
Calpain-4 (P=0.003)	0.139	0.061	0.034	0.074	0.068
Syk-c (P=0.494)	\	0.424	0.220	0.358	0.468
Syk-n (P=0.113)	\	\	0.112	0.166	0.208
MAP4 (P=0.064)	\	\	\	0.084	0.097